Magierowska-Jung M, Agut H, Katlama C, Autran B, Huraux J M
Laboratoire de Virologie CNRS EP 57. CERVI, Hôpital Pitié-Salpétrière, Paris, France.
J Med Virol. 1997 Jan;51(1):48-55.
Sequential isolates from four patients under zidovudine (ZDV) therapy were obtained using PBMC coculture in the absence or in the presence of 0.25 microM ZDV. PBMC-based HIV susceptibility assay demonstrated the emergence of ZDV-resistance in the sequential isolates from the four patients. Except in one case, the isolates obtained in the presence of ZDV did not exhibit a greater resistance pattern than their counterparts obtained in the absence of the drug. In parallel, partial reverse transcriptase gene sequence was determined directly on amplified products from proviral DNA. In addition to the mutations previously described at the critical codons 41, 67, 70, 215, and 219, numerous additional mutations were found in either ZDV-sensitive or ZDV-resistant isolates. The mutation Thr215Tyr was not observed in a case of highly resistant virus (ZDV IC50 > 6.25 microM), while the mutation Lys70Arg was found in either resistant or sensitive ones. The analysis of additional mutations did not reveal any clear pattern for ZDV resistance but pointed out the existence of highly variable regions neighbouring the five critical codons. Neither nucleotide sequence nor PBMC-based susceptibility assay provided unambiguous data about pretherapy isolates or early on-therapy isolates which could predict the emergence of ZDV resistance in further samples.
在不存在或存在0.25微摩尔齐多夫定(ZDV)的情况下,通过外周血单核细胞(PBMC)共培养获得了接受ZDV治疗的4名患者的序贯分离株。基于PBMC的HIV药敏试验表明,这4名患者的序贯分离株中出现了ZDV耐药性。除1例患者外,在有ZDV存在的情况下获得的分离株,其耐药模式并不比在无药物情况下获得的对应分离株更强。同时,直接对来自前病毒DNA的扩增产物测定部分逆转录酶基因序列。除了先前在关键密码子41、67、70、215和219处描述的突变外,在ZDV敏感或耐药分离株中还发现了许多其他突变。在1例高耐药病毒(ZDV IC50>6.25微摩尔)病例中未观察到Thr215Tyr突变,而在耐药或敏感病毒中均发现了Lys70Arg突变。对其他突变的分析未揭示ZDV耐药的任何明确模式,但指出了五个关键密码子附近存在高度可变区。核苷酸序列分析和基于PBMC的药敏试验均未提供关于治疗前分离株或治疗早期分离株的明确数据,而这些数据可以预测后续样本中ZDV耐药性的出现。